Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL / SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion from this visiting lecture series. This activity also includes downloadable slides from the series to improve care for your patients with CLL/SLL.
To claim credit: https://www.achlcme.org/btk-inhibitors-cll-sll-onctube